Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 17/20 | 0.69 |
| ▸ | WDR77 | Q9BQA1 | 13/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391303 | 1.00 | PRMT5 (0.69) | PRMT5WDR77SLC29A1 | |
| SCHEMBL20721501 | 0.86 | PRMT5 (0.58) | PRMT5WDR77 | |
| SCHEMBL29391785 | 0.85 | PRMT5 (0.52) | PRMT5WDR77 | |
| SCHEMBL20721584 | 0.85 | PRMT5 (0.52) | PRMT5WDR77 | |
| SCHEMBL20721413 | 0.84 | PRMT5 (0.71) | PRMT5WDR77 | |
| SCHEMBL29389042 | 0.84 | PRMT5 (0.71) | PRMT5WDR77 | |
| SCHEMBL29391290 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL20721426 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL28438103 | 0.79 | PRMT5 (0.59) | PRMT5WDR77 | |
| SCHEMBL20721601 | 0.73 | PRMT5 (0.58) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| EP-3952874-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | Prelude Therapeutics, Incorporated (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3939986-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | Prelude Therapeutics, Incorporated (US) | 2022-01-19 | — | — | EP | disclosed |
| US-11208416-B2 | Selective inhibitors of protein arginine methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208416-B2 | Selective inhibitors of protein arginine methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-12-28 | — | — | US | disclosed |
| US-11078205-B2 | Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078205-B2 | Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-08-03 | — | — | US | disclosed |
| CN-111527099-A | Selective inhibitors of protein arginine methyltransferase 5(PRMT5) | 普莱鲁德疗法有限公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-3665179-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | Prelude Therapeutics, Incorporated (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200148692-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200148692-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10570140-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570140-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190048014-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-02-14 | — | — | US | disclosed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20190048014-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078205-B2 | Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 142/4885SLC29A1 3372/4885 |
| US-20200148692-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 283/4885SLC29A1 3846/4885 |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 76/4885SLC29A1 3329/4885 |
| US-11208416-B2 | Selective inhibitors of protein arginine methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 283/4885SLC29A1 3846/4885 |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 283/4885SLC29A1 3846/4885 |
| US-10570140-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885SLC29A1 3944/4885 |
| US-20190048014-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885SLC29A1 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.